Navigation Links
Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
Date:3/25/2009

ety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have been treated with picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors. It is being studied in multiple cancer indications, treatment combinations and by two routes of administration.

In addition to the Phase 3 SPEAR trial in SCLC, picoplatin is also being evaluated in two ongoing Phase 2 clinical trials The first is evaluating the safety and efficacy of picoplatin in patients with metastatic colorectal cancer and the second in patients with castration-resistant (or hormone-refractory) prostate cancer. Oral picoplatin is also being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's results of clinical trials, business objectives and strategic goals, drug development plans, the potential safety and efficacy of its products in development and commercialization strategy. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptan
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary focus on ... Rajesh C. Shrotriya , MD, Chairman and Chief Executive ... Directors.  The appointment was made in connection with the ...
(Date:9/23/2014)... CARLOS, Calif. , Sept. 23, 2014 /PRNewswire/ ... company, today confirmed the initiation of human safety ... forms of addiction. A single dose of 18-MC, ... safety study conducted by Savant,s South American partner, ... experimental drug. Savant HWP plans to develop 18-MC ...
(Date:9/23/2014)... Sept. 23, 2014 Enable Injections , ... soon make it easy and nearly painless for patients ... their homes, has been named winner of the ,Buzz ... in the biotech sector.    Enable is one ... the greatest number of votes in the "Late Stage ...
Breaking Medicine Technology:CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 2Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 3Innovative Wearable Injector Developer, Enable Injections, Wins 'Buzz of BIO Investor Forum' 2
(Date:9/23/2014)... Pricing Healthcare announces its expansion into three ... 1. Prairie Spine & Pain Institute , (Peoria, ... recognized leader in spine procedures and pain management. ... on leading-edge, minimally invasive surgery techniques. The institute ... recovery times for patients. , 2. The Center ...
(Date:9/23/2014)... CA (PRWEB) September 23, 2014 Fountain Valley ... has won their latest body transformation contest and been named ... “Jennifer was raised here in Fountain Valley and still resides ... since June 2014 and she recently signed up for one ... been phenomenal,” says owner Zenia Joyner. “In just six weeks, ...
(Date:9/23/2014)... September 23, 2014 Maturo Medical ... Tempe, Arizona, announced Dr. Lisa Maturo has received ... from Worldlink Medical Academy. Dr. Maturo is ... have earned this credential. , World-renowned bioidentical ... Rouzier taught the rigorous training course, which trained ...
(Date:9/23/2014)... Angeles, CA (September 23, 2014) While many believe that ... a dangerous world, a new study finds that those ... despite this believed protection. This study was published today ... , Researchers David Etkin, Jelena Ivanova, Susan MacGregor, and ... those who believe in guardian angels, 68% said that ...
(Date:9/23/2014)... Santa Rosa, CA (PRWEB) September 23, 2014 ... by the arrival of the most technically advanced horticultural LED ... done it again with the XL750 and ... testers as well as the experienced horticulturalist, because it has ... over the light spectrum. Kind LED's grower-tested 12 band spectrum ...
Breaking Medicine News(10 mins):Health News:PricingHealthcare.com Adds Pricing Data for Pittsburgh, New Orleans, Peoria Facilities 2Health News:Fountain Valley Fit Body Boot Camp Announces Winner of Fitness Boot Camp Ambassador Contest 2Health News:Doctor Lisa Maturo of Maturo Medical Obtains Expert Certification in BioIdentical Hormone Replacement Therapy from World Link Medical 2Health News:Kind LED K5 Series XL1000 Grow Lights Sell Out in Only 2 Days 2
... Andhra women have financed the bypass surgery of a fisherwoman ... to their efforts, B. Hemavati, 35, wife of a fisherman ... operation at the Tirupati-based Sri Venkateswara Institute of Medical Sciences ... Godavari district, was diagnosed with a heart ailment that doctors ...
... computerized tomography (CBCT) is increasingly becoming a potent tool ... ,J. Martin Palomo and Mark Hans from the department ... of Dental Medicine and C.H. Kau and S. Richmond ... at the University of Wales' College of Medicine have ...
... identified by the Oregon National Primate Research Center at ... to control stem cells becoming other brain cells.// New ... and brain injury as a result of continued research. ... early stages before birth, which become glial cells in ...
... to the role religion plays in a patient's life positively ... for female medicos and no, for male medicos.// ... of the Southern Medical Journal, patients want their physicians to ... to discuss religious issues with them, especially if they are ...
... scientist at Schepens Eye Research Institute (SERI) found that ... television watching more enjoyable to the visually impaired. // ... develop an electronic device to help millions suffering eye ... include those suffering from macular degeneration, diabetic retinopathy and ...
... Zealand government plans to contain it. ,They are preparing ... It will be in multiple waves and will extend up to ... does not have facilities to // tackle such situations (pandemic). ... acute disasters. ,But in this case people are not ...
Cached Medicine News:Health News:Poor Andhra Women Enable Bypass Surgery Paying 50 Paise Each 2Health News:New Computerized Imaging Systems Help In Better Dental Treatment Planning 2Health News:Religious sensitivity of medicos gender-dependent 2Health News:Visually impaired prefer specially enhanced TV 2Health News:Visually impaired prefer specially enhanced TV 3
Whether you require high flow rates for critical situations or lower rates for others, this insufflator handles both situations equally well, regulated by the preselected pressure....
The TurboFlow 8000 has two separate gas output ports which, unlike many high flow insufflators, use standard-size tubing, each capable of providing up to 20 LPM flow....
Tongs...
ACMI™ COAG Bipolar Laparoscopy Probes provide 360 of hemostatis, bipolar safety, blunt dissection, irrigation, and suction in one instrument....
Medicine Products: